Personal information

Medical Oncology
France

Activities

Employment (2)

European Georges Pompidou Hospital , Paris Cancer Institute CARPEM, APHP.5 : Paris, FR

2018-11-01 to present | MD (Medical Oncology)
Employment
Source: Self-asserted source
Nicolas DELANOY

AP-HP: Paris, FR

2012-11-02 to 2018-10-31 | Interne (Oncologie médicale)
Employment
Source: Self-asserted source
Nicolas DELANOY

Education and qualifications (5)

Université Paris Descartes: Paris, Île-de-France, FR

2012-10-15 to 2018-10-31 | DES oncologie médicale
Education
Source: Self-asserted source
Nicolas DELANOY

Université Paris-Sud: Orsay, Île-de-France, FR

2015-10-01 to 2016-06-15 | Master 2 oncologie - biologie du cancer
Education
Source: Self-asserted source
Nicolas DELANOY

Université Pierre et Marie Curie: Paris, Île-de-France, FR

2014-09-01 to 2015-06-15 | CESAM - DIU statistiques
Education
Source: Self-asserted source
Nicolas DELANOY

Université Paris Descartes: Paris, Île-de-France, FR

2006-09-15 to 2012-10-15 | DCEM
Education
Source: Self-asserted source
Nicolas DELANOY

Université Paris Descartes: Paris, Île-de-France, FR

2007-10-15 to 2009-09-15 | Master 1 Génétique
Education
Source: Self-asserted source
Nicolas DELANOY

Works (21)

A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer

Cancers
2023-01 | Journal article | Author
Contributors: Marie Métairie; Louise Benoit; Meriem Koual; Enrica Bentivegna; Henri Wohrer; Pierre-Adrien Bolze; Yohan Kerbage; Emilie Raimond; Cherif Akladios; Xavier Carcopino et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.

Pharmaceuticals (Basel, Switzerland)
2021-08 | Journal article
Contributors: Velev M; Puszkiel A; Blanchet B; de Percin S; Delanoy N; Medioni J; Gervais C; Balakirouchenane D; Khoudour N; Pautier P et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?

Gynecologic oncology
2021-06 | Journal article
Contributors: Benoit L; Zerbib J; Koual M; Nguyen-Xuan HT; Delanoy N; Le Frère-Belda MA; Bentivegna E; Bats AS; Fournier L; Azaïs H
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study.

Cancers
2021-03 | Journal article
Contributors: Delanoy N; Robbrecht D; Eisenberger M; Sartor O; de Wit R; Mercier F; Geffriaud-Ricouard C; de Bono J; Oudard S
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

[Epithelial ovarian cancers and minimally invasive cytoreductive surgery after neoadjuvant chemotherapy: A systematic review].

Gynecologie, obstetrique, fertilite & senologie
2021-02 | Journal article
Contributors: Achen G; Koual M; Bentivegna E; Fournier L; Nguyen Xuan HT; Delanoy N; Bats AS; Azaïs H
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data.

Journal of clinical medicine
2021-01 | Journal article
Contributors: Seidler S; Koual M; Achen G; Bentivegna E; Fournier L; Delanoy N; Nguyen-Xuan HT; Bats AS; Azaïs H
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review.

Future oncology (London, England)
2020-12 | Journal article
Contributors: Pobel C; Auclin E; Procureur A; Clément-Zhao A; Simonaggio A; Delanoy N; Vano YA; Thibault C; Oudard S
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Pharmaceutical consultation to detect drug interactions in patients treated with oral chemotherapies: A descriptive cross-sectional study.

European journal of cancer care
2020-12 | Journal article
Contributors: Lachuer C; Perrin G; Chastel A; Aboudagga H; Thibault C; Delanoy N; Caudron E; Sabatier B
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

Gynecologic oncology
2020-07 | Journal article
Contributors: Derquin F; Floquet A; Hardy-Bessard AC; Edeline J; Lotz JP; Alexandre J; Pautier P; Angeles MA; Delanoy N; Lefeuvre-Plesse C et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Nephrotoxicity Associated With Niraparib.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2020-07 | Journal article
Contributors: Lazareth H; Delanoy N; Cohen R; Boissier E; Ayari H; Combe P; Crespel C; Mercadier-Riaz E; Karras A; Courbebaisse M et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].

Annales de pathologie
2020-02 | Journal article
Contributors: Koual M; Perkins G; Delanoy N; Crespel C; Medioni J; Nguyen-Xuan HT; Douay-Hauser N; Blons H; Le Frère-Belda MA; Molière D et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials.

European journal of cancer (Oxford, England : 1990)
2019-12 | Journal article
Contributors: Robbrecht DG; Delanoy N; Tannock IF; Tombal B; Eisenberger M; Fizazi K; Sartor O; Mercier F; Oudard S; de Wit R
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.

European journal of cancer (Oxford, England : 1990)
2019-11 | Journal article
Contributors: Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

The impact of the Paris terrorist attacks on the mental health of resident physicians.

BMC psychiatry
2019-02 | Journal article
Contributors: Gregory J; de Lepinau J; de Buyer A; Delanoy N; Mir O; Gaillard R
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

The Lancet. Haematology
2018-12 | Journal article
Contributors: Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

European urology oncology
2018-06 | Journal article
Contributors: Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.

Clinical genitourinary cancer
2018-02 | Journal article
Contributors: Angelergues A; Efstathiou E; Gyftaki R; Wysocki PJ; Lainez N; Gonzalez I; Castellano DE; Ozguroglu M; Carbonero IG; Flechon A et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis.

2015-11 | Journal article
Contributors: Delanoy N; Pécuchet N; Fabre E; Combe P; Juvin K; Pujade-Lauraine E; Oudard S
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central

2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel

European Journal of Cancer
2015-09 | Journal article
Contributors: A. Angelergues; J. Bellmunt; E. Efstathiou; I. Gonzalez; R. Gyftaki; N. Delanoy; M. Ozguroglu; A. Flechon; A. Guillot; S. Le Moulec et al.
Source: Self-asserted source
Nicolas DELANOY via Crossref Metadata Search

2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting

European Journal of Cancer
2015-09 | Journal article
Contributors: S. Oudard; A. Angelergues; E. Efstathiou; I. Gonzalez; R. Gyftaki; N. Delanoy; M. Ozguroglu; A. Flechon; A. Guillot; S. Le Moulec et al.
Source: Self-asserted source
Nicolas DELANOY via Crossref Metadata Search

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

2014-06 | Journal article
Contributors: Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C et al.
Source: Self-asserted source
Nicolas DELANOY via Europe PubMed Central